Immunotherapeutics

Leukemia: Juvaris is developing JVRS-100 as an immunotherapeutic to treat acute leukemias. When administered systemically, the drug is believed to induce NK and T-cell directed anti-tumor effects through induction of innate immunity. Currently available treatments for acute myelogenous leukemia are characterized by short responses and profound toxicity contributing to rapid mortality. Over 25,000 patients are currently undergoing treatment in the US. JVRS-100 has demonstrated effectiveness in experimental leukemia animal models and is advancing into clinical development with grant funding from a leading academic institution.

Animal Health: Juvaris' immunotherapy technology is being developed by Bayer HealthCare AG for the treatment of infectious disease and cancer for companion animals in the veterinary field. Programs are underway to develop immunotherapies to treat and/or prevent disease in a variety of animal species.

^ back to top